Abstract
Children and adolescents who acquired HIV perinatally and are on lifelong antiretroviral therapy (ART) are at increased risk of lipid abnormalities, premature atherosclerosis, and early onset cardiovascular diseases (CVD). Majority of these children reside in sub-Saharan Africa, where monitoring of lipid profiles is not routine. In this study, we assessed the age dependent prevalence of dyslipidemia among children and adolescents who acquired HIV in Ghana.
In this cross-sectional study we examined lipid profiles of 397 children aged 6 to 18 years. Dyslipidemia was defined by elevated total cholesterol (TC) (≥200 mg/dL) or triglyceride (TG) levels (>150 mg/dL) or low-density lipoprotein cholesterol (LDL-C) (>130 mg/dL) or reduced high-density lipoprotein cholesterol (HDL-C) (<35 mg/dL). Dyslipidemia prevalence, by at least one criterion and for each criterion separately, was compared between age groups 6 - 12 (pre-teen) and 13 - 18 (teenage) years, as well as by sex.
The overall prevalence of dyslipidemia was 42.32%, and by individual criterion was 9.07% using LDL-C, 11.84% using TC, 15.87% using TG, and 24.00% using HDL-C. Additionaly, 5.04% (n=20) of the participants showed abnormalities across three parameters. Teenagers had a higher overall prevalence of dyslipidemia (46.75% vs. 39.04%, p=0.12). Criterion-based dyslipidemia prevalence varied across age groups, with TC-based (14.04% vs. 8.88%, p=0.12) being higher in the pre-teen group, while elevated TG-based (20.12% vs. 12.72%, p=0.05) and low levels of HDL- based (28.99% vs. 20.60%, p=0.05) were more prevalent in the teenagers. The mean levels of TC (p=0.04) and LDL-C (p=0.03) were significantly higher in the pre-teen age groups. Females had nearly twice as high as that of males with prevalence of abnormal LDL-C levels (11.39% vs. 6.67%, p=0.13).
This study showed a high prevalence of dyslipidemia among children who acquired HIV perinatally and are on ART, with age-related variations in lipid profiles. These findings emphasize the importance of implementing routine monitoring for lipid disorders within this population.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
Yes
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
approved by the Institutional Review Boards of the Ghana Health Service (Protocol # GHS-ERC: 025/09/21) and the Noguchi Memorial Institute for Medical Research, University of Ghana (Protocol # CPN 015/21-22).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.